Conventional wisdom is that the health care sector, particularly pharmaceutical companies, may be able to withstand the global economic downturn because they supply necessary consumer services and products. Biotechnology companies that provide some of the more medically promising technologies, however, will only continue to grow if we provide them with the economic incentive to incur massive developmental and regulatory approval costs and to tolerate lengthy periods of testing and the substantial risk of failure.